Biosimilars of omalizumab

Biosimilars/General | Posted 19/08/2016 post-comment0 Post your comment

Last update: 3 November 2017

Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes [1]. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

Molecular genetics UCL V16G29

The originator product, Novartis’s Xolair (omalizumab), is indicated for the treatment of moderate to severe persistent asthma and chronic idiopathic urticaria despite antihistamine treatment.

Xolair was approved by the US Food and Drug Administration (FDA) on 20 June 2003 and by the European Medicines Agency (EMA) on 25 October 2005 [1]. Xolair had worldwide sales of US$835 million in 2016.

The patents on Xolair will expire in the US on 20 June 2017 and in Europe in August 2017 [1]. Some of the omalizumab biosimilars and non-originator biologicals* approved or in development are presented in Table 1.

Table 1: Biosimilars and non-originator biologicals* of omalizumab approved or in development

Company name, Country Product name Stage of development
Glenmark Pharmaceuticals, India* GBR 310 Received FDA clearance for first-in-human trial in April 2017
Sorrento Therapeutics/MabTech, USA/China* STI-004 Phase II/III trial completed in May 2016 [2]
FDA: US Food and Drug Administration.
*See editor’s comment

US-based biopharmaceutical company Sorrento Therapeutics (Sorrento) announced on 16 May 2016 that its partner, MabTech had successfully completed a combined phase II and III clinical trial in China for STI-004, a copy biological for omalizumab (Xolair) [2].

Editor’s comment
It should be noted that ‘copy biologicals’ approved in China might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related articles
Biosimilars of basiliximab

Biosimilars of tocilizumab

Biosimilars of eculizumab

Biosimilars of rituximab

Biosimilars of ranibizumab

1. Derbyshire M. Patent expiry dates for biologicals: 2016 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(1):27-30. doi:10.5639/gabij.2017.0601.006
2. GaBI Online - Generics and Biosimilars Initiative. Positive phase III results for omalizumab copy biological []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 19]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: EMA, Novartis

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010